Inventiva S.A. Stock Price, News & Analysis
Company Description
Inventiva S.A. American Depositary Shares (NASDAQ: IVA) represents a France-based biopharmaceutical company that operates in the research and development in biotechnology industry within the broader professional, scientific, and technical services sector. According to available information, Inventiva focuses on discovering and developing drug candidates that act on nuclear receptors, transcription factors and epigenetic modulation.
The company is described as concentrating its efforts on the development of its product candidate lanifibranor for the treatment of patients with non-alcoholic steatohepatitis (NASH), a liver disease for which there are stated to be no approved therapies. In addition to lanifibranor, Inventiva is involved in a portfolio of pre-clinical therapy programs. These programs are reported to address therapeutic areas that include oncology, fibrosis and rare diseases.
Business focus and activities
Inventiva operates in a segment described as service delivery and clinical stage research. Its activities relate notably to therapies in oncology, fibrosis and rare diseases. The company’s operations are reported as being located in France. A significant part of its revenue is stated to be derived from research partnerships with AbbVie and Boehringer Ingelheim (BI), reflecting a collaboration-driven model in which external partnerships play an important role in funding and advancing its research programs.
The company has American Depositary Shares (ADSs), each representing one ordinary share of Inventiva S.A., listed in the United States. A Form 6-K filed in November 2025 describes an underwriting agreement with Leerink Partners LLC and Piper Sandler & Co. for a public offering of ADSs under a shelf registration statement on Form F-3. This filing indicates that Inventiva uses U.S. capital markets to support its research and development activities.
Regulatory and reporting profile
Inventiva files as a foreign private issuer under the Exchange Act on Form 20-F, as indicated in multiple Form 6-K filings. The company regularly furnishes current reports on Form 6-K that include press releases, notices of shareholder meetings, proxy materials, and interim financial reports. For example, Form 6-K filings in October and November 2025 reference press releases, a management report on financial statements for the six months ended June 30, 2025, and documentation related to an Ordinary and Extraordinary General Meeting.
These filings show that Inventiva provides information to investors through periodic press releases and regulatory documents, including notices of general meetings, proxy cards and voting instructions for holders of American Depositary Shares. The company also uses Form 6-K to incorporate certain materials by reference into its shelf registration statement on Form F-3.
Location and corporate structure
In its SEC filings, Inventiva S.A. identifies its principal executive offices as being in Daix, France. The filings list the company’s name as Inventiva S.A. and describe it as a foreign issuer that reports under the Exchange Act using Form 20-F. All operations are reported as being in France, which aligns with its characterization as a France-based biopharmaceutical company.
Partnerships and revenue sources
According to the Polygon description, a majority of Inventiva’s revenue is derived from research partnerships with AbbVie and Boehringer Ingelheim. These partnerships suggest that the company’s business model relies significantly on collaboration with larger pharmaceutical organizations to support its research programs and generate revenue from its scientific expertise and development activities.
Capital markets activity
The Form 6-K dated November 13, 2025 describes an underwriting agreement for a public offering of American Depositary Shares under a shelf registration statement on Form F-3. The filing explains that the offering is made pursuant to this registration statement and related prospectus supplements, and that the company granted the underwriters a 30-day option to purchase additional ADSs. The filing notes that the underwriting agreement contains customary representations, warranties, conditions to closing, indemnification obligations and termination provisions, and that the full text of the agreement is filed as an exhibit.
Other Form 6-K filings reference interim financial reports and the incorporation by reference of certain exhibits into the Form F-3 registration statement. This pattern of filings indicates that Inventiva uses SEC-registered offerings and related documentation to raise capital for its biopharmaceutical research and development activities.
Governance and shareholder meetings
Form 6-K filings dated October 20, 2025 and November 7, 2025 describe the publication of a notice of meeting for an Ordinary and Extraordinary General Meeting of shareholders to be held in Paris, France. Another Form 6-K dated October 30, 2025 notes that the company began mailing a proxy card and voting instructions to beneficial owners of American Depositary Shares in connection with this General Meeting. These filings show how Inventiva communicates with its shareholders and ADS holders regarding corporate governance matters and voting procedures.
Board-level connections
A news release from Ligand Pharmaceuticals Incorporated notes that an individual serving as a board member of France-based Inventiva (listed on Euronext Paris and Nasdaq under the symbol IVA) was appointed to Ligand’s board of directors. This reference confirms that Inventiva’s shares are traded both on Euronext Paris and on Nasdaq in the form of American Depositary Shares, and that the company participates in international corporate governance networks within the biopharmaceutical industry.
Summary
Overall, Inventiva S.A. American Depositary Shares (IVA) provide U.S. investors with exposure to a France-based biopharmaceutical company focused on research and development in biotechnology. The company emphasizes drug candidates acting on nuclear receptors, transcription factors and epigenetic modulation, with a particular focus on lanifibranor for NASH and additional pre-clinical programs in oncology, fibrosis and rare diseases. Its operations are based in France, and it generates a significant portion of its revenue from research partnerships with AbbVie and Boehringer Ingelheim. Through regular SEC filings and capital markets activity, Inventiva maintains a presence in U.S. public markets while conducting its research and development activities in France.
Stock Performance
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Short interest in Inventiva S.A. (IVA) currently stands at 115.7 thousand shares, up 32.9% from the previous reporting period, representing 0.1% of the float. Over the past 12 months, short interest has decreased by 67.5%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Inventiva S.A. (IVA) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The days to cover has decreased 96.1% over the past year, suggesting improved liquidity for short covering. The ratio has shown significant volatility over the period, ranging from 1.0 to 55.2 days.